1. Record Nr. UNINA9910522910603321

Titolo	Urologic oncology : multidisciplinary care for patients / / edited by Kelly L. Stratton and Alicia K. Morgans
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022] ©2022
ISBN	3-030-89891-1
Descrizione fisica	1 online resource (491 pages)
Disciplina	616.99461
Soggetti	Genitourinary organs - Cancer Internal medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Contents -- Contributors -- Chapter 1: Creating a Multidisciplinary Clinic -- Introduction -- Historical Perspective -- The Multidisciplinary Clinic at Sidney Kimmel Cancer Center Thomas Jefferson University -- Impact of Multidisciplinary Care -- Establishing a Multidisciplinary Clinic -- Conclusion -- References -- Chapter 2: Supportive and Palliative Care for Genitourinary Malignancies -- Prostate Cancer: Identity -- Vasomotor Symptoms -- Sexual Health and Intimacy -- Kidney Cancer: Variability -- Unique Treatment Toxicity and Adherence -- Adherence and Persistence with Oral Agents -- Decisional Conflict Regarding Cytoreductive Nephrectomy -- Prognostic Uncertainty -- Bladder Cancer: Vulnerability -- Dilemmas in Choice of Urinary Diversion -- Ostomy Care and Management -- Neobladder Care and Management -- Frailty -- Overlapping Supportive Care -- Comprehensive Pain Management -- Antiresorptive Therapy for Palliation of Bone Pain -- Mood Disorders -- Nausea and Vomiting -- Chronic Lower Urinary Tract Symptoms -- Hematuria -- Palliative Care -- References -- Chapter 3: Operationalizing Genetic Testing in the Care of Patients with Prostate Cancer -- Introduction -- Germline Genetic Testing -- Prostate Cancer Genetics -- Genetic Testing Models -- Identifying Patients Appropriate for Genetic Counseling and Testing -- Pre-test Education and Informed Consent -- Test Selection -- Results Delivery -- Somatic Testing -- Cascade Testing -- Identifying

and Overcoming Barriers -- Cementing the Genetic and GU Clinical Team Partnership -- Patient Disparities -- Key Takeaway -- References -- Chapter 4: High-Risk Localized Prostate Cancer -- Defining High-Risk Prostate Cancer -- Treatment -- Observation -- Radiation and ADT -- Duration of ADT -- Combination Radiotherapy -- Surgery for High-Risk Prostate Cancer -- Salvage Therapies for High-Risk Disease.
Treatment of Adverse Pathological Findings Versus Treatment for Failure -- Treatment of Node-Positive Disease -- Surgery After Failure of Radiation Therapy -- Future Directions -- Radiation and Novel Hormone Therapies -- Conclusion -- References -- Chapter 5: Treatment of Metastatic Hormone-Sensitive Prostate Cancer -- Introduction -- Agents Demonstrating Overall Survival Improvement in mHSPC -- Docetaxel -- Abiraterone Acetate -- Novel Anti-Androgens -- Apalutamide -- Enzalutamide -- Agents with No Proven Benefit in mHSPC -- Bisphosphonates -- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) -- Comparative Efficacy and Sequencing of Agents in mHSPC -- Localized Therapies: Surgery, Radiation to the Primary Tumor, and Metastasis-Directed Therapies in Oligometastatic HSPC -- Emerging Therapies -- Conclusions -- Summary of Key Points -- References -- Chapter 6: Expanding Options for M0 Castration-Resistant Prostate Cancer (CRPC) -- Introduction -- Metastasis-Free Survival (MFS) and Advanced Prostate Cancer Research -- Therapeutic Options in M0 CRPC -- Enzalutamide -- Apalutamide -- Darolutamide -- Agents Under Investigation -- M0 CRPC and Meta-data -- Adverse Events and Side Effects in M0 CRPC Treatment -- Managing M0 CRPC in Clinical Practice -- References -- Chapter 7: Immunotherapy for Metastatic Prostate Cancer -- Introduction -- Approved Immunotherapies for Prostate Cancer -- Sipuleucel-T -- Immunotherapy Based on Biomarkers in Prostate Cancer -- Evaluations of Immunotherapy in Unselected Patients -- Ipilimumab -- Pembrolizumab -- Investigating Combinations of Immunotherapy in Prostate Cancer -- Ipilimumab and Nivolumab -- Enzalutamide and PD-1/PD-L1 Inhibitors -- Cabozantinib and Atezolizumab -- Olaparib and Durvalumab -- Future Directions -- Conclusion -- References -- Chapter 8: Advances in Prostate Cancer Imaging -- Introduction.
PET Imaging Techniques for Prostate Cancer -- F-18 Sodium Fluoride PET/CT or PET/MRI Bone Scan (F-18 NaF PET Bone Scan) -- F-18 Fluorodeoxyglucose (FDG) PET -- C-11 Choline or F-18-Choline PET -- F-18 Fluciclovine -- Ga-68 or F-18 Prostate-Specific Membrane Antigen (PSMA) -- F-18 Fluorodehydrotestosterone PET (F-18 FDHT PET) -- Localized Disease/Initial Staging -- Magnetic Resonance Imaging (MRI) -- PET Imaging Probes -- Biochemical Recurrent (BCR) Prostate Cancer -- C-11 Choline or F-18 Choline PET -- F-18 Fluciclovine -- Ga-68 or F-18 Prostate-Specific Membrane Antigen (PSMA) -- Metastatic Prostate Cancer -- Treatment Response -- Biologic Characterization -- Theranostics -- References -- Chapter 9: Bone Health Management -- Introduction -- Physiology of Bone Remodeling -- Evaluation of Bone Mineral Density -- Pathophysiology of Bone Metastasis in Prostate Cancer -- Treatment-Related Bone Loss -- Consequences of Glucocorticoids -- Consequences of Androgen Deprivation Therapy -- Consequences on Bone Metabolism -- Management of Bone Health and Bone Metastases (Tables 9.3 and 9.4 -- Fig. 9.1) -- Bone-Targeted Agents: Bisphosphonates and Denosumab (Table 9.5) -- Prevention and Treatment of Osteoporosis and Fragility Fractures -- Prevention of Skeletal-Related Events -- Safety of Bone-Targeted Agents -- Other Therapies

and Risk Stratification -- Tumor Biology and Genetics -- Risk Stratification -- Endoscopic/Cystoscopic Treatment and Management -- Transurethral Resection of Bladder Tumor (TURBT) -- Surveillance -- Intravesical BCG -- Bacillus Calmette-Guerin (BCG) -- Mechanism of Action -- Induction and Maintenance Regimens -- Risks/Adverse Reactions -- BCG Failure -- Intravesical Chemotherapy -- Chemotherapy Post-TURBT -- Adjuvant Intravesical Chemotherapy -- Low-Risk NMIBC -- Intermediate-Risk NMIBC -- Mitomycin C (MMC). Mechanism of Action.